Innovus Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Innovus Pharmaceuticals, Inc.
Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.
Thierry Laugel, managing partner of the Paris-based financiers, tells Scrip about the virtues of its 'company creation model,' giving innovative ideas time to mature rather than rushing to the market.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Beyond Human, LLC
- FasTrack Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.